These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21343454)

  • 1. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.
    Liang B; Bai N; Cai Y; Wang R; Drlica K; Zhao X
    Antimicrob Agents Chemother; 2011 May; 55(5):2409-12. PubMed ID: 21343454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.
    Campion JJ; Chung P; McNamara PJ; Titlow WB; Evans ME
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2189-99. PubMed ID: 15917512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutant selection window in rabbits infected with Staphylococcus aureus.
    Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
    J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK; Borsos SD; Blondeau JM
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
    Firsov AA; Alieva KN; Strukova EN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Romanov AV; Edelstein MV; Zinner SH
    J Antimicrob Chemother; 2017 Nov; 72(11):3100-3107. PubMed ID: 28981793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T; Hori T; Sugimori G; Yamano Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
    Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of recA on levofloxacin exposure-related resistance development.
    Singh R; Ledesma KR; Chang KT; Tam VH
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4262-8. PubMed ID: 20660686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
    Murillo O; Doménech A; Garcia A; Tubau F; Cabellos C; Gudiol F; Ariza J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4011-7. PubMed ID: 17015630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
    Tasso L; de Andrade C; Dalla Costa T
    Int J Antimicrob Agents; 2011 Oct; 38(4):307-13. PubMed ID: 21802907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.